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Although the essentials for resistance control are well 
known [l], the medical community worldwide has 
seemed rather incapable of reacting to increasing anti- 
microbial resistance. There are several reasons for this, 
but the most apparent is that we have too long ignored 
bacteria. Antibiotic use has led to the recent situation 
in two ways. First, the extensive use of these agents is 
causing the development and spread of resistance. 
Second, if we had no antibiotics and the bacterial 
infections could not be treated, we would have learnt 
more about the dynamics of the bacterial flora during 
the last decades. Antibiotics have practically destroyed 
the development of modern medical bacteriology. 
Today, the spread of antibiotic-resistant bacteria 
gives us a concrete reason to try to better understand 
the bacterial world. The example of the wide spread 
of methicillin-resistant Staphylococcus aureus (MRSA) 
into almost all European hospitals shows that hygienic 
measures have been late or inadequate. Although the 
spread of MRSA may have happened despite the best 
possible hygienic barriers and clever antibiotic policy, 
it is a warning example of how bacteria can spread. 
In most countries, there has been no common 
antibiotic policy in outpatients. Practice has developed 
mostly according to the marketing efforts of the 
pharmaceutical industry. The marketing of the new 
antibacterial drugs has led to increased use of these 
agents, although their use may not have been indicated. 
Because antimicrobials have an influence on the 
common and shared microbial flora, there should also 
be a common strategy on how antimicrobial agents are 
used in community settings. In hospitals, antibiotic 
policy is planned and followed by the infectious disease 
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professionals and the hygienic program committee. 
Because every hospital is different, general antibiotic 
policy is difficult to create. However, recent guidelines 
form a good basis for hospital hygiene programs and 
proper antibiotic policy [2]. 
To create or study different antibiotic policy options 
in the community, two databases are needed, covering 
surveillance of bacterial resistance, and antibiotic usage 
patterns. When all the data are available, the first step 
is to study the relationships between bacterial resistance 
and antibiotic usage in different geographic areas [3,4]. 
The second step is to try to limit the spread of bacterial 
resistance by controlled interventions using different 
antibiotic policies [ 5 ] .  The final goal is to try to find 
the antibiotic policy, in other words, the combination 
of different antibiotics in different indications, that 
selects least resistant bacteria. Because there are many 
different important clinical pathogens and also anti- 
microbial agents, the result will always be a compromise. 
The research should be concentrated on the most 
important bacterial pathogens and the most used anti- 
microbial agents. 
STUDIES ON ANTIBIOTIC USAGE AND INCIDENCE 
OF RESISTANCE 
In the community, there are only a few studies com- 
paring antimicrobial use and bacterial resistance at the 
local level. This is due to the lack of comprehensive 
information on bacterial resistance and antibiotic con- 
sumption. 
Baquero et al [6] reported one of the first 
correlations between antibiotic use and bacterial resist- 
ance. The occurrence of penicillin-resistant Streptococcus 
pneumoniae was linked to increased use of amino- 
penicillins in different geographic areas in Spain. 
Seppala et al [4] reported a statistically significant 
( p  <0.006) correlation between usage of erythromycin 
and occurrence of erythromycin-resistant Streptococcus 
pyogenes in a total of 206 healthcare districts in Finland. 
The use of erythromycin and also the amount of 
erythromycin-resistant Streptococcus pyogenes were 
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highest among children [4]. In Iceland, Arason et a1 [7] 
described a link between recent antimicrobial use and 
penicillin-resistant pneumococci in children (see also 
Kristinsson in this issue). 
In addition to the antimicrobial usage, many social, 
behavioral and bacterial factors influence the spread of 
resistant bacteria in the community [4,8]. These include 
hygienic conditions in the study area, the population 
density, the number of children in the study area 
(children are heavy users of antibiotics), and the 
transportation networks. In addition, the network for 
drug distribution should be taken into account when 
geographic relationships are studied [4]. Of the microbe- 
linked factors, the characteristics and the spreading 
mechanisms of the microorganism studied should be 
taken into account. Also, other factors, such as plasmid- 
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Figure 1 I&: Resistance to erythromycin in group A streptococci in various health authority areas in Finland in 1992. For 
better depiction of the data, resistance rates are kvided into three classes, each encompassing an equal number of health 
authority areas (black areas, resistance 218.8%; dark grey areas, 10.6-18.7%; and white areas, 0-10.5%). Right: Consumption 
of erythromycin in Finland. Adjusted consumption figures (in defined daily doses, DDDs, per 1 .OOO inhabitants per day) are 
divided into three classes, each encompassing an equal number of health authority areas (black areas, 22.09 DDDs; dark grey 
areas, 1.77-2.08 DDDs; and white areas, 0-1.76 DDDs). The association is statistically significant (p=0.006) between 
erythromycin consumption and erythromycin resistance in group AS streptococci. From: Seppala et a1 1231. Published with 
the permission of Clinical Infectious Diseases and the authors. 
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Figure 2 Use of macrolide antimicrobial agents in Finland in 1976-97. (Data source: Finnish Statistics on Medicines 
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Figure 3 Erythromycin resistance of group A streptococci in Finland in 1990-97. The annual number of the isolates varies 
from 5662 to 10 162. (Data source: Seppza et al [5] and the Finnish Study Group for Antimicrobial Resistance.) 
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mediated resistance transfer or chromosomal mutation 
rate, and the presence of human reservoirs of resistant 
genes or other related resistant bacteria, may be of 
iniportance. 
In hospitals, a link between bacterial resistance and 
the use of antimicrobials has been shown in many 
studies, although the relationship can be complex, with 
additional factors involved [9-121. The nature of 
hospitals varies greatly, and there is a need for more 
studies where similar types of hospital are compared. 
Antibiotic restrictions have been effective in controlling 
resistance problems in hospitals, but usually they have 
been linked to improved hospital hygienic measures. 
When compared to the situation in the community, the 
number of possible intervention targets is much higher 
in hospital; some of these are personnel devoted to 
hospital hygiene, restrictions and ad hoc guidelines of 
antibiotic use, controlled hand hygiene and patient 
isolation [2]. 
Mathematical models have been developed to 
predict the development of bacterial resistance under 
conditions of known antibiotic selection pressure. 
Levin et a1 and Bonhoeffer et a1 [13,14] have developed 
a model of the population genetics of antibiotic 
resistance in the commensal flora. Models for the same 
purpose have also been developed by Austin et a1 [15]. 
These models have not yet been extensively tested in 
different clinical conditions. The model described by 
Seppala et a1 [4] is more a statistical than a mathematical 
model. The purpose of this model is to compare 
existing data on the antimicrobial usage and occurrence 
of resistance. 
In theory, there are several ways to study the 
relationship between antibiotic usage and the incidence 
of bacterial resistance. The first approach is long-term 
study where resistance and antibiotic consumption 
are followed in one particular area for several years, 
preferably for more than 10 years, to discover reliable 
trends [15,16]. Another approach is to compare different 
areas with different antimicrobial consumption patterns 
14.51 (Figure 1). It is likely, however, that the possible 
relationship between the usage of antimicrobial agents 
and bacterial resistance can be shown only if there is a 
suitable ‘window’. This window is a situation where 
there are differences in resistance levels in different 
areas, in other words, resistant bacteria are actively 
spreading. If bacterial resistance is already at a high 
level, it may be difficult to find any correlation between 
the usage of antimicrobials and bacterial resistance. 
When more resistance surveillance and antibiotic 
consumption data are available, there will certainly 
be more attempts to test and develop mathematical 
modeling. 
INTERVENTIONS TO CONTROL BACTERIAL RESISTANCE IN 
THE COMMUNITY 
The first intervention to try to decrease bacterial 
resistance in the community occurred in Japan, where 
decreased consumption of erythromycin led to decreased 
levels of erythromycin-resistant Streptocorcus pyogenes in 
the 1970s [17]. However, detailed data on the nature of 
the action are lacking. In Iceland, wide-scale inter- 
vention has led to decreased levels of penicillin-resistant 
Streptococcus pneumoniae. This action plan is described in 
detail by Kristinsson in this issue. 
In Finland, increasing usage of erythromycin was 
followed by increased resistance among group A 
streptococci in the 1980s [3,18]. In 1991, a recom- 
mendation was made to decrease the use of macrolides 
in infections typically caused by group A streptococci, 
such as tonsillitis and skin infections [19]. This recom- 
mendation nearly halved the usage of macrolides in all 
parts of the country (Figure 2). During the follow-up, 
we showed that the macrolide resistance of group A 
streptococci decreased from 19% to 9% (p<O.OOl; 
Figure 3). This decrease is most probably due to the 
decreased use of macrolides in tonsillitis and skin 
infections [20]. Before the recommendation, erythro- 
mycin was used in about 10% of the tonsillitis patients 
(they are supposed to be penicillin hypersensitive), and 
after the recommendation in only about 1%. Our 
hypothesis is that macrolides did not any longer ‘meet’ 
Streptococcus pyogenes in vivo. Because macrolides were 
still rather widely used in other indications, asymp- 
tomatic carriers of Streptococcus pyogenes were certainly 
also treated. However, the amount of Strepfucoccus 
pyogenes bacteria in the carrier state is much lower than 
in clinical infections. We believe that the small amount 
of Streptoroccur pyogenes bacteria in these carriers does 
not significantly increase the niacrolide resistance. 
The report from the EU Conference, The 
Copenhagen Recommendation [21], clearly states that 
intervention studies are needed to solve ‘the microbial 
threat’. In Finland, we have recently launched a 5-year, 
country-wide MIKSTRA program, where our main 
goal is to develop optimal antibiotic policy for out- 
patient infections. This includes new evidence-based 
recommendations for diagnosis and treatment of the 
most common outpatient infections with a careful 
follow-up, cost-benefit analysis of the new recommen- 
dations, educational initiatives for both health profes- 
sionals and the public, as well as measurement of the 
changes in the attitudes of the health professionals and 
public. Changes in bacterial resistance of the most 
common community pathogens will be surveyed by the 
Finnish Study Group for Antimicrobial Resistance, 
a network of 37 clinical microbiology laboratories. 
4 S 1 6  C l in ica l  M i c r o b i o l o g y  a n d  In fec t ion ,  V o l u m e  5 S u p p l e m e n t  4 
This network collects susceptibility data of more than 
200 000 bacterial isolates annually. The main goal is to 
register possible effects of the changes in antimicrobial 
consumption on the bacterial resistance. In Finland, 
more than 3 million courses of antibiotics are used in 
outpatients annually; the population size in Finland is 
5.1 million. In addition to the total number of anti- 
biotic courses, the pattern of the different classes of 
antibiotics used in different infections needs revision 
There is also a need for individual-based studies 
concerning antibiotic usage and development of bacterial 
resistance. Guillemot et al [22] recently described a very 
important study where bacterial resistance was linked 
to the dosage of the p-lactam antibiotic used. They 
suggested that a low daily dosage and long duration of 
treatment promotes pharyngeal carriage of penicillin- 
resistant Streptococcus pneumoniae. In addition, long- 
term, individual-based follow-up studies are needed to 
develop prudent antibiotic policies. 
In conclusion, much more effort has to be directed 
at the study of the relationship between antibiotic usage 
and the incidence of bacterial resistance. The need for 
antibiotic policy research is immediate, because every 
year several hundreds of millions of antibiotic courses 
are used in outpatients in Europe. In principle, every 
course increases bacterial resistance. Are we ready- 
without any attempt to improve the situation-to 
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